MIGUEL A RODRIGUEZ-BIGAS to Chemoradiotherapy
This is a "connection" page, showing publications MIGUEL A RODRIGUEZ-BIGAS has written about Chemoradiotherapy.
Connection Strength
0.626
-
A Phase II Study of Capecitabine/Oxaliplatin With Concurrent Radiotherapy in Locally Advanced Squamous Cell Carcinoma of the Anal Canal. Clin Colorectal Cancer. 2019 12; 18(4):301-306.
Score: 0.092
-
Hyperfractionated Accelerated Reirradiation for Patients With Recurrent Anal Cancer Previously Treated With Definitive Chemoradiation. Am J Clin Oncol. 2018 07; 41(7):632-637.
Score: 0.086
-
Definitive Chemoradiation for Squamous Cell Carcinoma of the Rectum. Am J Clin Oncol. 2017 Apr; 40(2):163-166.
Score: 0.079
-
Postoperative chemotherapy use after neoadjuvant chemoradiotherapy for rectal cancer: Analysis of Surveillance, Epidemiology, and End Results-Medicare data, 1998-2007. Cancer. 2014 Apr 15; 120(8):1162-70.
Score: 0.063
-
Preoperative radiation therapy with concurrent capecitabine, bevacizumab, and erlotinib for rectal cancer: a phase 1 trial. Int J Radiat Oncol Biol Phys. 2014 Feb 01; 88(2):301-5.
Score: 0.063
-
Long-term results of weekly/daily cisplatin-based chemoradiation for locally advanced squamous cell carcinoma of the anal canal. Cancer. 2013 Nov 01; 119(21):3769-75.
Score: 0.061
-
Pretreatment high-resolution rectal MRI and treatment response to neoadjuvant chemoradiation. Dis Colon Rectum. 2012 Apr; 55(4):371-7.
Score: 0.056
-
Definitive Intensity-Modulated Chemoradiation for Anal Squamous Cell Carcinoma: Outcomes and Toxicity of 428 Patients Treated at a Single Institution. Oncologist. 2022 02 03; 27(1):40-47.
Score: 0.028
-
Benchmarking Outcomes for Definitive Treatment of Young-Onset, Locally Advanced Rectal Cancer. Clin Colorectal Cancer. 2022 03; 21(1):e28-e37.
Score: 0.027
-
Who Should Get Lateral Pelvic Lymph Node Dissection After Neoadjuvant Chemoradiation? Dis Colon Rectum. 2019 10; 62(10):1158-1166.
Score: 0.023
-
Locally Recurrent Disease Related to Anal Canal Cancers. Surg Oncol Clin N Am. 2017 01; 26(1):115-125.
Score: 0.019
-
Quantified pathologic response assessed as residual tumor burden is a predictor of recurrence-free survival in patients with rectal cancer who undergo resection after neoadjuvant chemoradiotherapy. Cancer. 2013 Dec 15; 119(24):4231-41.
Score: 0.015
-
ACR appropriateness criteria???resectable rectal cancer. Radiat Oncol. 2012 Sep 24; 7:161.
Score: 0.014